较低危骨髓增生异常综合征的治疗进展

付蓉; 陶景莲

doi:10.13201/j.issn.1004-2806.2019.11.003

较低危骨髓增生异常综合征的治疗进展

付蓉^,,
陶景莲

- 天津医科大学总医院血液内科(天津, 300052)

详细信息

通讯作者: 付蓉,E-mail:florai@vip.com

中图分类号: R733

收稿日期: 2019-06-25

Progress in the treatment of low-risk myelodysplastic syndrome

FU Rong^,,
TAO Jinglian

More Information

Corresponding author: FU Rong, E-mail: florai@vip.com

Received Date: 25 June 2019

摘要

- 骨髓增生异常综合征 /
- 较低危组 /
- 治疗
- myelodysplastic syndromes /
- low-risk /
- treatment

HTML全文

参考文献(51)

[1]	Moyo V,Lefebvre P,Duh MS,et al.Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes:a meta-analysis[J].Ann Hematol,2008,87:527-536.
[2]	Platzbecker U,Symeonidis A,Oliva EN,et al.A phase 3 randomized placebo-controlled trial of darbepoetin alfa in patients with anemia and lower-risk myelodysplastic syndromes[J].Leukemia,2017,31:1944-1950.
[3]	Giagounidis A,Mufti GJ,Fenaux P,et al.Results of a randomized,double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia[J].Cancer,2014,120:1838-1846.
[4]	Fenaux P,Muus P,Kantarjian H,et al.Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes:long-term safety and efficacy[J].Br J Haematol,2017,178:906-913.
[5]	Kantarjian HM,Fenaux P,Sekeres MA,et al.Long-term follow-up for up to 5 years on the risk of leukaemic progression in thrombocytopenic patients with lower-risk myelodysplastic syndromes treated with romiplostim or placebo in a randomised double-blind trial[J].Lancet Haematol,2018,5:e117-e126.
[6]	Mavroudi I,Pyrovolaki K,Pavlaki K,et al.Effect of the nonpeptide thrombopoietin receptor agonist eltrombopag on megakaryopoiesis of patients with lower risk myelodysplastic syndrome[J].Leuk Res,2011,35:323-328.
[7]	Santini V,Fenaux P.Treatment of myelodysplastic syndrome with thrombomimetic drugs[J].Semin Hematol,2015,52:38-45.
[8]	Oliva E,Santini V,Zini G,et al.Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes:Results of a Prospective,Randomized,Trial[J].Haematologica,2013,98:456-456.
[9]	Oliva EN,Alati C,Santini V,et al.Eltrombopag versus placebo for low-risk myelodysplastic syndromes with thrombocytopenia (EQoL-MDS):phase 1 results of a single-blind,randomised,controlled,phase 2 superiority trial[J].Lancet Haematol,2017,4:e127-e136.
[10]	Brierley CK,Steensma DP.Thrombopoiesis-stimulating agents and myelodysplastic syndromes[J].Br J Haematol,2015,169:309-323.
[11]	Swaminathan M,Borthakur G,Kadia TM,et al.A phase 2 clinical trial of eltrombopag for treatment of patients with myelodysplastic syndromes after hypomethylating-agent failure[J].Leuk Lymphoma,2019 Feb 18:1-7.doi:10.1080/10428194.2019.1576873.[Epub ahead of print].
[12]	Choi EJ,Lee JH,Park HS,et al.Androgen therapy for lower-risk myelodysplastic syndrome[C].Blood,2018,132.
[13]	Ganan-Gomez I,Wei Y,Starczynowski DT,et al.Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes[J].Leukemia,2015,29:1458-1469.
[14]	Wang C,Yang Y,Gao S,et al.Immune dysregulation in myelodysplastic syndrome:Clinical features,pathogenesis and therapeutic strategies[J].Crit Rev Oncol Hematol,2018,122:123-132.
[15]	Komrokji RS,Mailloux AW,Chen DT,et al.A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction[J].Haematologica,2014,99:1176-1183.
[16]	Passweg JR,Giagounidis AA,Simcock M,et al.Immunosuppressive therapy for patients with myelodysplastic syndrome:a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care——SAKK 33/99[J].J Clin Oncol,2011,29:303-309.
[17]	Haider M,Al Ali N,Padron E,et al.Immunosuppressive Therapy:Exploring an Underutilized Treatment Option for Myelodysplastic Syndrome[J].Clin Lymphoma Myeloma Leuk,2016,16 Suppl:S44-S48.
[18]	Hata T,Tsushima H,Baba M,et al.Long-term outcome of immunosuppressive therapy for Japanese patients with lower-risk myelodysplastic syndromes[J].Int J Hematol,2013,98:687-693.
[19]	Santini V.Treatment of low-risk myelodysplastic syndromes[J].Hematology Am Soc Hematol Educ Program,2016,2016:462-469.
[20]	Kronke J,Fink EC,Hollenbach PW,et al.Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS[J].Nature,2015,523:183-188.
[21]	Stahl M,Zeidan AM.Lenalidomide use in myelodysplastic syndromes:Insights into the biologic mechanisms and clinical applications[J].Cancer,2017,123:1703-1713.
[22]	Oliva EN,Lauseker M,Aloe Spiriti MA,et al.Early lenalidomide treatment for low and intermediate-1 International Prognostic Scoring System risk myelodysplastic syndromes with del(5q) before transfusion dependence[J].Cancer Med,2015,4:1789-1797.
[23]	Komrokji RS,List AF.Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes[J].Ann Oncol,2016,27:62-68.
[24]	Fenaux P,Giagounidis A,Selleslag D,et al.A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q[J].Blood,2011,118:3765-3776.
[25]	List AF,Bennett JM,Sekeres MA,et al.Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS[J].Leukemia,2014,28:1033-1040.
[26]	Bejar R,Stevenson KE,Caughey B,et al.Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem-cell transplantation[J].J Clin Oncol,2014,32:2691-2698.
[27]	Sekeres MA,Swern AS,Giagounidis A,et al.The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)[J].Blood Cancer J,2018,8:90.
[28]	Santini V,Almeida A,Giagounidis A,et al.Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents[J].J Clin Oncol,2016,34:2988-2996.
[29]	Sibon D,Cannas G,Baracco F,et al.Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents[J].Br J Haematol,2012,156:619-625.
[30]	Toma A,Kosmider O,Chevret S,et al.Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion[J].Leukemia,2016,30:897-905.
[31]	Wang ES,Lyons RM,Larson RA,et al.A randomized,double-blind,placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide[J].J Hematol Oncol,2012,5:71.
[32]	Blatt K,Herrmann H,Hoermann G,et al.Identification of campath-1(CD52) as novel drug target in neoplastic stem cells in 5q-patients with MDS and AML[J].Clin Cancer Res,2014,20:3589-3602.
[33]	Neukirchen J,Platzbecker U,Sockel K,et al.Real life experience with alemtuzumab treatment of patients with lower-risk MDS and a hypocellular bone marrow[J].Ann Hematol,2014,93:65-69.
[34]	Wang H,Zhang TT,Jin S,et al.Pyrosequencing quantified methylation level of miR-124 predicts shorter survival for patients with myelodysplastic syndrome[J].Clin Epigenetics,2017,9:91.
[35]	Zhao G,Li N,Li S,et al.High methylation of the 4-aminobutyrate aminotransferase gene predicts a poor prognosis in patients with myelodysplastic syndrome[J].Int J Oncol,2019,54:491-504.
[36]	Cao ZJ,Ma J.Efficacy and Safety of Low-Dose Decitabine in Low-or Intermediate 1-Risk MDS[C].Blood,2018,132.
[37]	Park S,Hamel JF,Toma A,et al.Outcome of lower-risk patients with myelodysplastic syndromes without 5q deletion after failure of erythropoiesis-stimulating agents[J].J Clin Oncol,2017,35:1591-1597.
[38]	Jabbour E,Short NJ,Montalban-Bravo G,et al.Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN[J].Blood,2017,130:1514-1522.
[39]	Lee BH,Kang KW,Jeon MJ,et al.Survival Benefit with Standard-Dose Decitabine Versus Standard-Dose Azacitidine in Patients with Lower-Risk Myelodysplastic Syndromes[C].Blood,2018,132.
[40]	Inoue H,Morita Y,Rai S,et al.Azacitidine therapy for low-risk myelodysplastic syndrome developing after solid organ transplantation[J].Rinsho Ketsueki,2017,58:138-142.
[41]	Gattermann N,Rachmilewitz EA.Iron overload in MDS-pathophysiology,diagnosis,and complications[J].Ann Hematol,2011,90:1-10.
[42]	Chai X,Li D,Cao X,et al.ROS-mediated iron overload injures the hematopoiesis of bone marrow by damaging hematopoietic stem/progenitor cells in mice[J].Sci Rep,2015,5:10181.
[43]	Greenberg PL,Stone RM,Al-Kali A,et al.Myelodysplastic Syndromes,Version 2.2017,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2017,15:60-87.
[44]	Angelucci E,Li JM,Greenberg PL,et al.Safety and Efficacy,Including Event-Free Survival,of Deferasirox Versus Placebo in Iron-Overloaded Patients with Low-and Int-1-Risk Myelodysplastic Syndromes (MDS):Outcomes from the Randomized,Double-Blind Telesto Study[C].Blood,2018,132.
[45]	Zeidan AM,Giri S,DeVeaux M,et al.Systematic review and meta-analysis of the effect of iron chelation therapy on overall survival and disease progression in patients with lower-risk myelodysplastic syndromes[J].Ann Hematol,2019,98:339-350.
[46]	Garcia-Manero G,Sasaki K,Montalban-Bravo G,et al.A Phase II Study of Nivolumab or Ipilimumab with or without Azacitidine for Patients with Myelodysplastic Syndrome (MDS)[C].Blood,2018,132.
[47]	Garcia-Manero G,Jabbour EJ,Konopleva MY,et al.A Clinical Study of Tomaralimab (OPN-305),a Toll-like Receptor 2(TLR-2) Antibody,in Heavily Pre-Treated Transfusion Dependent Patients with Lower Risk Myelodysplastic Syndromes (MDS) That Have Received and Failed on Prior Hypomethylating Agent (HMA) Therapy[C].Blood,2018,132.
[48]	Zhao X,Tian X,Kajigaya S,et al.Epigenetic landscape of the TERT promoter:a potential biomarker for high risk AML/MDS[J].Br J Haematol,2016,175:427-439.
[49]	Steensma DP,Platzbecker U,Van Eygen K,et al.Imetelstat Treatment Leads to Durable Transfusion Independence (TI) in RBC Transfusion-Dependent (TD),Non-Del(5q) Lower Risk MDS Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Who Are Lenalidomide (LEN) and HMA Naive[C].Blood,2018,132.
[50]	Fenaux P,Kiladjian JJ,Platzbecker U.Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis[J].Blood,2019,133:790-794.
[51]	Platzbecker U,Germing U,Gotte KS,et al.Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS):a multicentre,open-label phase 2 dose-finding study with long-term extension study[J].Lancet Oncol,2017,18:1338-1347.